Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL).

Authors :: Jacobson, C.
Hemmer, M. T.
Hu, Z.
Frank, M.
Popplewell, L.
Ahmed, N.
Lin, Y.
Best, T.
Beygi, S.
Miao, H.
Fu, C.
Sun, F.
Xu, H.
Pasquini, M. C.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p375-376, 2p
Publication Year :: 2023
Abstract: Encore Abstract - previously submitted to ASCO 2023 and EHA 2023 The research was funded by: The research was funded by: Kite, a Gilead Company. The following pts were excluded: no consent, prior non-transplant cellular therapy, and FL grade 3b or 3a/3b unspecified. B Background: b Axicabtagene ciloleucel (axi-cel) is an autologous CAR T-cell therapy approved for adult patients (pts) with R/R FL after >=2 lines of systemic therapy. [Extracted from the article]

Full Text Access

Tools